{"id":4345,"date":"2026-11-16T09:00:00","date_gmt":"2026-11-16T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4345"},"modified":"2026-11-17T20:41:55","modified_gmt":"2026-11-18T00:41:55","slug":"cd7-targeted-aav-expands-immune-cell-engineering","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4345","title":{"rendered":"CD7 Targeted AAV Expands Immune Cell Engineering"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"512\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_Nanjing_University_AAV_APR31_Technology_and_Modalities-768x512.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4351\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_Nanjing_University_AAV_APR31_Technology_and_Modalities-768x512.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_Nanjing_University_AAV_APR31_Technology_and_Modalities-300x200.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_Nanjing_University_AAV_APR31_Technology_and_Modalities-1024x683.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_Nanjing_University_AAV_APR31_Technology_and_Modalities.png 1536w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Nanjing University (academic)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Peer-reviewed publication (Nature Biotechnology)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Engineered AAV capsid for T and NK cell gene delivery<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>AAV.APR31<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>CD7; AAVR (cell entry)<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Hematologic and solid tumors (mouse models)<\/p>\n<h4>Summary<\/h4>\n<p>A Nature Biotechnology paper reports an evolved AAV capsid, AAV.APR31, that enters primary human T and NK cells at approximately 100\u20131,000-fold lower vector doses than AAV6 and supports transient transfer, targeted knock-in and transposon insertion. Human therapeutic safety, in-vivo human targeting and manufacturing performance are not established.<\/p>\n<p>Hong and colleagues evolved AAV6 in primary T cells, identified an APR capsid motif, and implicated CD7 alongside AAVR in entry. At matched MOIs of 100\u20131,000, mesothelin CAR knock-in ranged 36.8\u201372.4% with APR31 versus 0.92\u201318.9% with AAV6. Engineered cells controlled tumors in hematologic and solid-tumor mouse models. The article was accepted 14 September and published online 16 November; inventors disclose a patent filing.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> one capsid enabling ex-vivo and in-vivo engineering across T and NK cells could reduce vector dose, expand manufacturing choices and support modular CAR, TCR and gene-editing payloads. Matched human-cell comparisons and mechanism support this. Counterpoint: lower MOI does not yet translate to lower clinical cost or toxicity.<\/p>\n<p><strong>Interpretation B:<\/strong> CD7-mediated entry may improve lymphoid selectivity in vivo; mouse tumor control is encouraging, but human CD7 expression, AAVR dependence, pre-existing AAV immunity, tissue distribution and dose-limiting liver exposure may erode selectivity. Integrating transposons and CRISPR knock-in have distinct insertion and genotoxicity risks. Durability, cytokine release, off-tissue transduction, scalable capsid production and licensing rights must be tested independently.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>CD7 is a T- and NK-lineage surface protein. APR31 is an AAV capsid variant engineered for lymphoid entry; it carries genetic payloads but does not itself encode a particular therapeutic target. CAR-T and CAR-NK products may target tumor antigens such as CD19, mesothelin or GD2.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Peer-reviewed mechanism and preclinical function verified; no human treatment data.<\/li>\n<li>Missing: human in-vivo biodistribution, vector genome dose-response, immune memory, integration mapping, GMP yield and freedom to operate.<\/li>\n<li>Upgrade: reproducible primate lymphoid targeting with acceptable exposure and first-human editing; downgrade: off-tissue transduction or integration-linked clonal expansion.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>APR31 is a strong delivery-platform signal for engineered immune cells, while its clinical advantage remains conditional on selective, safe systemic delivery.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 5 of 5. Signal Direction: positive. Confidence in Facts: high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Nature Biotechnology paper reports an evolved AAV capsid, AAV.APR31, that enters primary human T and NK cells at approximately 100\u20131,000-fold lower vector doses than AAV6 and supports transient transfer, targeted knock-in and transposon&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4351,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1508,1189,1507],"class_list":["post-4345","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-aav-apr31","tag-car-t-2","tag-nanjing-university"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4345"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4345\/revisions"}],"predecessor-version":[{"id":4361,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4345\/revisions\/4361"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4351"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}